A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Public ClinicalTrials.gov record NCT07851220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
Study identification
- NCT ID
- NCT07851220
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2026 (Estimated)
- Primary completion
- Sep 27, 2031 (Estimated)
- Completion
- Sep 26, 2033 (Estimated)
- Last update posted
- Oct 1, 2026
2026 – 2033
United States locations
- U.S. sites
- 4
- U.S. states
- 2
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Academic Medical Research Institute | Los Angeles | California | 90022 | Recruiting |
| Bioresearch Partner-Jackson West | Doral | Florida | 33122 | Recruiting |
| Bioresearch Partner- Martin Luther King Jr. | Miami | Florida | 33127 | Recruiting |
| Bioresearch Partner- Pembroke Pines | Pembroke Pines | Florida | 33029 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07851220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07851220 live on ClinicalTrials.gov.